[go: up one dir, main page]

CR10644A - Vacunas y metodos para controlar adiposidad - Google Patents

Vacunas y metodos para controlar adiposidad

Info

Publication number
CR10644A
CR10644A CR10644A CR10644A CR10644A CR 10644 A CR10644 A CR 10644A CR 10644 A CR10644 A CR 10644A CR 10644 A CR10644 A CR 10644A CR 10644 A CR10644 A CR 10644A
Authority
CR
Costa Rica
Prior art keywords
adiposity
vaccines
methods
control
immunoconjugates
Prior art date
Application number
CR10644A
Other languages
English (en)
Inventor
P Zorrilla Eric
M Meijler Michael
D Janda Kim
Original Assignee
Leandro P Rizzuto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leandro P Rizzuto filed Critical Leandro P Rizzuto
Publication of CR10644A publication Critical patent/CR10644A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/60Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invencion preenta los inmunoconjugados para impedir el aumento de peso y tratar la obesidad en un sujeto. Los inmunoconjugados comprenden los polipeptidos de ghrelina y un grupo molecular portador adecuado.
CR10644A 2006-08-01 2009-02-26 Vacunas y metodos para controlar adiposidad CR10644A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82107106P 2006-08-01 2006-08-01

Publications (1)

Publication Number Publication Date
CR10644A true CR10644A (es) 2009-04-16

Family

ID=38997839

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10644A CR10644A (es) 2006-08-01 2009-02-26 Vacunas y metodos para controlar adiposidad

Country Status (15)

Country Link
US (1) US9675679B2 (es)
EP (1) EP2046376B1 (es)
JP (1) JP2009545618A (es)
KR (1) KR101510082B1 (es)
CN (1) CN101500602A (es)
AU (1) AU2007281131B2 (es)
BR (1) BRPI0715345A8 (es)
CA (1) CA2659264C (es)
CR (1) CR10644A (es)
EA (1) EA200970166A1 (es)
IL (1) IL196720A0 (es)
MA (1) MA30637B1 (es)
MX (1) MX2009001133A (es)
NO (1) NO20090439L (es)
WO (1) WO2008016976A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8992928B2 (en) 2006-02-11 2015-03-31 Victor Raso Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin
WO2010089757A2 (en) * 2008-11-07 2010-08-12 Usv Limited An improved process for synthesis of cyclic octapeptide
CA2826853C (en) * 2011-02-09 2020-10-27 The Scripps Research Institute Ghrelin mimetic polypeptide hapten immunoconjugates having improved solubility and immunogenicity and methods of use thereof
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
JPWO2017170494A1 (ja) * 2016-03-29 2019-02-14 国立大学法人 東京大学 抗肥満ワクチン

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
IL147652A0 (en) * 1999-07-23 2002-08-14 Kangawa Kenji Novel peptides
GB2357084A (en) * 1999-12-06 2001-06-13 Amersham Pharm Biotech Uk Ltd A hydrophobic carrier peptide
EP1353683A4 (en) * 2000-05-30 2004-05-12 Merck & Co Inc ANALOGS BY GHRELIN
NZ537001A (en) * 2002-07-19 2007-04-27 Cytos Biotechnology Ag A composition comprising a virus-like particle and at least ghrelin or a ghrelin-derived peptide bound thereto
EP1407779A1 (en) * 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
KR101157694B1 (ko) * 2003-12-17 2012-06-20 와이어쓰 엘엘씨 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법
JP2007518762A (ja) * 2004-01-20 2007-07-12 サイトス バイオテクノロジー アーゲー グレリン−担体結合体
CA2603295A1 (en) * 2004-04-07 2006-10-20 Gastrotech Pharma A/S Use of ghrelin for the treatment of hyperthyroidism
JP2008515771A (ja) * 2004-07-14 2008-05-15 イーライ リリー アンド カンパニー 抗グレリン抗体
US7572451B2 (en) * 2004-10-25 2009-08-11 Cytos Biotechnology Ag Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof
US8992928B2 (en) * 2006-02-11 2015-03-31 Victor Raso Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin

Also Published As

Publication number Publication date
WO2008016976A3 (en) 2008-09-25
US20100021487A1 (en) 2010-01-28
MX2009001133A (es) 2009-02-11
WO2008016976A2 (en) 2008-02-07
EP2046376A4 (en) 2010-01-27
AU2007281131B2 (en) 2012-11-29
MA30637B1 (fr) 2009-08-03
NO20090439L (no) 2009-03-19
CA2659264A1 (en) 2008-02-07
IL196720A0 (en) 2011-08-01
BRPI0715345A8 (pt) 2019-01-08
JP2009545618A (ja) 2009-12-24
KR101510082B1 (ko) 2015-04-10
WO2008016976A8 (en) 2009-08-06
CN101500602A (zh) 2009-08-05
US9675679B2 (en) 2017-06-13
EA200970166A1 (ru) 2009-06-30
AU2007281131A1 (en) 2008-02-07
BRPI0715345A2 (pt) 2013-06-18
EP2046376B1 (en) 2018-08-01
WO2008016976B1 (en) 2008-11-06
CA2659264C (en) 2016-01-26
EP2046376A2 (en) 2009-04-15
KR20090041416A (ko) 2009-04-28

Similar Documents

Publication Publication Date Title
CR10644A (es) Vacunas y metodos para controlar adiposidad
CL2007000311A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
DK2308514T3 (da) Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
CY1120297T1 (el) Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων
BRPI1011519A2 (pt) marcador ancorado, sistema de marcador ancorado e sistema de liberação de marcador de âncora.
BRPI0911987A2 (pt) suturas e métodos heterofuncionais codificados.
EP2891648A4 (en) AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT THEREWITH
EP2225204A4 (en) CARBAZOLE DERIVATIVE AND LIGHT EMITTING ELEMENT, LIGHT-EMITTING DEVICE AND ELECTRONIC DEVICE USING THE CARBAZOLE DERIVATIVE USE
BRPI1008532A2 (pt) "composições, métodos e usos para arcabouço com base no domínio fibronectina tipo iii".
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
PT2172211E (pt) Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
BRPI0816318A2 (pt) Dispositivo de liberação transdérmica, e, método para preparar o mesmo
CR10008A (es) Antagonistas de activina-activina tipo ii a y sus usos para promover el crecimiento de los huesos
DK2381983T3 (da) Lægemiddeladministrationsanordning, der omfatter stempelstang med dosismarkeringer
EA201100268A1 (ru) Вакцина
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
EP2891653A4 (en) AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT THEREWITH
NL1036050C (nl) Brandvertragende en brandwerende samenstelling.
PL2026651T3 (pl) Terapia kombinowana za pomocą nieselektywnych inhibitorów COX dla zapobiegania uszkodzeń żołądka związanych z COX
EP2159217A4 (en) AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE THEREWITH
BRPI0916705A2 (pt) polipeptídeo isolado, polinucleotídeo isolado, composição farmacêutica, composição imunogênica, método para tratamento ou prevenção de tuberculose, e, usos de um polipeptídeo, e de um polinucleotídeo.
BRPI0910378A2 (pt) composições imunogênicas anti-amilóides, métodos e usos
BRPI0912133A2 (pt) artigo resitente á penetração, e, uso do mesmo.
BRPI1011348A2 (pt) aparelho para impulsionar postes e estacas no solo.
EA201100359A1 (ru) Инсектицидные комбинации

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)